News

Themis announces exclusive licensing agreement with Max-Planck-Innovation to develop and commercialize oncolytic virotherapies

Details

Themis announced today that it has entered into a license agreement with Max-Planck-Innovation GmbH, the technology transfer agency of the Max Planck Society in Germany, granting it exclusive worldwide license to develop, manufacture and commercialize therapies based on an oncolytic measles virus platform that was jointly developed by the Eberhard-Karls-University Tübingen and the Max Planck Institute for Biochemistry. 

sphingotec raises €20 million from HBM and Wellington Partners

Details

German diagnostics company sphingotec GmbH has closed a €20m growth equity financing round led by international healthcare specialist investors HBM and Wellington Partners. Sphingotec will primarily use the proceeds to roll out the fully automated IB 10 point-of-care (POC) platform for testing of a broad panel of acute blood biomarkers, which had been acquired in May 2018 through an acquisition of Samsung-subsidiary Nexus Dx Inc. 

Carisma Therapeutics announces $53 million Series A financing

Details

Carisma Therapeutics Inc., formerly CARMA Therapeutics, a privately-held biotechnology company focused on the development of macrophage-based immunotherapeutics, today announced the close of a $53 million Series A financing to further expand its CAR-Macrophage platform – the first technology to combine antigen recognition with the effector function of macrophages – and to rapidly drive its programs toward clinical development. 

  1. TRiCares closes €22 million Series B financing round
  2. 4SC: Yakult Honsha joins pivotal RESMAIN study of resminostat in CTCL
  3. CEPI partners with Themis to advance vaccines against Lassa fever and MERS
  4. Themis establishes Scientific Advisory Board of experts in virology and vaccine development
© Wellington Partners, 2019.